Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $50.67 Average PT from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $54.50.

A number of research analysts have recently issued reports on ORKA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. UBS Group initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Wedbush increased their price target on Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Barclays started coverage on Oruka Therapeutics in a research note on Monday, October 13th. They issued an “overweight” rating and a $48.00 price objective on the stock. Finally, Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $31.81, for a total value of $222,670.00. Following the completion of the sale, the insider owned 1,518 shares in the company, valued at $48,287.58. The trade was a 82.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 24.69% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. bought a new position in shares of Oruka Therapeutics during the 3rd quarter worth about $39,000. Russell Investments Group Ltd. acquired a new position in Oruka Therapeutics during the 3rd quarter worth approximately $43,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after acquiring an additional 904 shares in the last quarter. Legal & General Group Plc acquired a new stake in Oruka Therapeutics in the second quarter valued at approximately $28,000. Finally, Ameritas Investment Partners Inc. bought a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $31,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Trading Down 4.5%

Shares of ORKA opened at $33.00 on Friday. The stock’s 50-day moving average price is $31.15 and its two-hundred day moving average price is $23.97. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $36.51. The company has a market capitalization of $1.60 billion, a PE ratio of -17.37 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. Equities research analysts predict that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.